Impact of patients' refusal to undergo adjuvant treatment measures on survival.

PURPOSE: Breast cancer patients receive treatment recommendations from multidisciplinary tumour boards. To determine the consequences of patients' refusal of such recommendations, we analysed the database of the Centre for Breast Cancer at the Ortenau Clinic in Offenburg, Germany. METHODS: A total of 4315 patients with non-metastatic primary breast cancer, treated between 1997 and 2019, were analysed with descriptive analyses, Kaplan-Meier survival analyses, and Cox regression analyses regarding the effects of their refusal. RESULTS: About 10.7% of the patients rejected the treatment advice. These were significantly elderly (F = 74.4; p < 0.001; one-way ANOVA), with greater tumour size (F = 36.7; p < 0.001; one-way ANOVA), a higher number of affected lymph nodes (F = 4.2; p = .039; one-way ANOVA), and more poorly differentiated tumours (χ2 = 16.8; df = 2; p < 0.001). The refusal of adjuvant treatment resulted in higher rates of local recurrences (χ2radiotherapy = 109.1; df = 1; p < 0.001, χ2chemotherapy = 18.3; df = 1; p < 0.001, χ2endocrine = 32.5; df = 1; p < 0.001) and poorer overall survival (χ2radiotherapy = 184.9; df = 6; p < 0.001; χ2chemotherapy = 191.8; df = 6; p < 0.001). CONCLUSIONS: All parts of the adjuvant treatment of breast cancer are clearly associated with improvements regarding disease-free and overall survival. To answer open questions about the background of patients' refusal, an analysis of prospective data collections seems necessary. In addition, patient communication should be improved so that patients understand the background of the multidisciplinary tumour board and the potential consequences of their refusal.

Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study.

BACKGROUND: Endocrine treatment (ET) with an aromatase inhibitor (AI) is the treatment of choice in post-menopausal patients with hormone receptor-positive early breast cancer (EBC). However, adverse events (AEs) often lead to treatment discontinuation. This analysis aimed to identify side-effects that lead to patients failing to persist with letrozole treatment. PATIENTS AND METHODS: Post-menopausal hormone receptor-positive EBC patients starting ET with letrozole were enroled in EvAluate-TM, a non-interventional study. Information regarding treatment compliance and persistence was gathered in months 6 and 12. Persistence was defined as the time from 30 d after the start to the end of treatment. The influence on persistence of musculoskeletal syndrome, menopausal disorder, sleep disorder and other AEs within the first 30 d was analysed using Cox regression analyses. RESULTS: Among 3887 patients analysed, the persistence rate after 12 months was >85%. In all, 568 patients (14.6%) discontinued the treatment, 358 of whom (63.0%) did so only because of side-effects. The main AEs influencing persistence were musculoskeletal symptoms (hazard ratio [HR] 2.55; 95% confidence interval [CI], 1.90-3.42), sleep disorders (HR 1.95; 95% CI, 1.41-2.70) and other AEs (HR 2.03; 95% CI, 1.51-2.73). Menopausal disorder was not associated with non-persistence (HR 1.17; 95% CI, 0.74-1.84). CONCLUSIONS: These results suggest that side-effects of AIs such as musculoskeletal syndrome and sleep disorder lead to ET discontinuation within the first treatment year in significant numbers of EBC patients. Compliance programmes adapted for subgroups that are at risk for early non-persistence might help to ensure the recommended therapy duration. CLINICAL TRIALS NUMBER: CFEM345DDE19.

Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients.

Background: Patients' compliance and persistence with endocrine treatment has a significant effect on the prognosis in early breast cancer (EBC). The purpose of this analysis was to identify possible reasons for non-persistence, defined as premature cessation of therapy, on the basis of patient and tumor characteristics in individuals receiving adjuvant treatment with letrozole. Patients and methods: The EvAluate-TM study is a prospective, multicenter, noninterventional study in which treatment with the aromatase inhibitor letrozole was evaluated in postmenopausal women with hormone receptor-positive EBC in the early therapy phase. Treatment persistence was evaluated at two pre-specified study visits after 6 and 12 months. As a measure of early therapy persistence the time from the start to the end of treatment (TTEOT) was analyzed. Cox regression analyses were carried out to identify patient characteristics and tumor characteristics predicting TTEOT. Results: Out of the total population of 3941 patients with EBC, 540 (13.7%) events involving treatment cessation unrelated to disease progression were observed. This was due to drug-related toxicity in the majority of cases (73.5%). Persistence rates were 92.2%, 86.9%, and 86.3% after 6, 12, and 15 months, respectively. The main factors influencing premature treatment discontinuation were older age [hazard ratio (HR) 1.02/year], comorbidities (HR 1.06 per comorbidity), low body mass index, and lower tumor grade (HR 0.85 per grade unit). Conclusion: These results support the view that older, multimorbid patients with low tumor grade and low body mass index are at the greatest risk for treatment discontinuation and might benefit from compliance and support programs.

Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study.

Introduction: The EvaluateTM study (Evaluation of therapy management and patient compliance in postmenopausal hormone receptor-positive breast cancer patients receiving letrozole treatment) is a prospective, non-interventional study for the assessment of therapy management and compliance in the routine care of postmenopausal women with invasive hormone receptor-positive breast cancer receiving letrozole. The parameters for inclusion in the study are presented and discussed here. Material and Methods: Between January 2008 and December 2009 a total of 5045 patients in 310 study centers were recruited to the EvaluateTM study. Inclusion criteria were hormone receptor-positive breast cancer and adjuvant treatment or metastasis. 373 patients were excluded from the analysis for various reasons. Results: A total of 4420 patients receiving adjuvant treatment and 252 patients with metastasis receiving palliative treatment were included in the study. For 4181 patients receiving adjuvant treatment, treatment with the aromatase inhibitor letrozole commenced immediately after surgery (upfront). Two hundred patients had initially received tamoxifen and started aromatase inhibitor treatment with letrozole at 1-5 years after diagnosis (switch), und 39 patients only commenced letrozole treatment 5-10 years after diagnosis (extended endocrine therapy). Patient and tumor characteristics were within expected ranges, as were comorbidities and concurrent medication. Conclusion: The data from the EvaluateTM study will offer a good overview of therapy management in the routine care of postmenopausal women with hormone receptor-positive breast cancer. Planned analyses will look at therapy compliance and patient satisfaction with how information is conveyed and the contents of the conveyed information.

Reliable detection of fluence anomalies in EPID-based IMRT pretreatment quality assurance using pixel intensity deviations.

PURPOSE: This work uses repeat images of intensity modulated radiation therapy (IMRT) fields to quantify fluence anomalies (i.e., delivery errors) that can be reliably detected in electronic portal images used for IMRT pretreatment quality assurance. METHODS: Repeat images of 11 clinical IMRT fields are acquired on a Varian Trilogy linear accelerator at energies of 6 MV and 18 MV. Acquired images are corrected for output variations and registered to minimize the impact of linear accelerator and electronic portal imaging device (EPID) positioning deviations. Detection studies are performed in which rectangular anomalies of various sizes are inserted into the images. The performance of detection strategies based on pixel intensity deviations (PIDs) and gamma indices is evaluated using receiver operating characteristic analysis. RESULTS: Residual differences between registered images are due to interfraction positional deviations of jaws and multileaf collimator leaves, plus imager noise. Positional deviations produce large intensity differences that degrade anomaly detection. Gradient effects are suppressed in PIDs using gradient scaling. Background noise is suppressed using median filtering. In the majority of images, PID-based detection strategies can reliably detect fluence anomalies of ≥5% in ∼1 mm(2) areas and ≥2% in ∼20 mm(2) areas. CONCLUSIONS: The ability to detect small dose differences (≤2%) depends strongly on the level of background noise. This in turn depends on the accuracy of image registration, the quality of the reference image, and field properties. The longer term aim of this work is to develop accurate and reliable methods of detecting IMRT delivery errors and variations. The ability to resolve small anomalies will allow the accuracy of advanced treatment techniques, such as image guided, adaptive, and arc therapies, to be quantified.

A method to evaluate dose errors introduced by dose mapping processes for mass conserving deformations.

PURPOSE: To present a method to evaluate the dose mapping error introduced by the dose mapping process. In addition, apply the method to evaluate the dose mapping error introduced by the 4D dose calculation process implemented in a research version of commercial treatment planning system for a patient case. METHODS: The average dose accumulated in a finite volume should be unchanged when the dose delivered to one anatomic instance of that volume is mapped to a different anatomic instance-provided that the tissue deformation between the anatomic instances is mass conserving. The average dose to a finite volume on image S is defined as d(S)=e(s)/m(S), where e(S) is the energy deposited in the mass m(S) contained in the volume. Since mass and energy should be conserved, when d(S) is mapped to an image R(d(S→R)=d(R)), the mean dose mapping error is defined as Δd(m)=|d(R)-d(S)|=|e(R)/m(R)-e(S)/m(S)|, where the e(R) and e(S) are integral doses (energy deposited), and m(R) and m(S) are the masses within the region of interest (ROI) on image R and the corresponding ROI on image S, where R and S are the two anatomic instances from the same patient. Alternatively, application of simple differential propagation yields the differential dose mapping error, Δd(d)=|∂d∂e*Δe+∂d∂m*Δm|=|(e(S)-e(R))m(R)-(m(S)-m(R))m(R) (2)*e(R)|=α|d(R)-d(S)| with α=m(S)/m(R). A 4D treatment plan on a ten-phase 4D-CT lung patient is used to demonstrate the dose mapping error evaluations for a patient case, in which the accumulated dose, D(R)=∑(S=0) (9)d(S→R), and associated error values (ΔD(m) and ΔD(d)) are calculated for a uniformly spaced set of ROIs. RESULTS: For the single sample patient dose distribution, the average accumulated differential dose mapping error is 4.3%, the average absolute differential dose mapping error is 10.8%, and the average accumulated mean dose mapping error is 5.0%. Accumulated differential dose mapping errors within the gross tumor volume (GTV) and planning target volume (PTV) are lower, 0.73% and 2.33%, respectively. CONCLUSIONS: A method has been presented to evaluate the dose mapping error introduced by the dose mapping process. This method has been applied to evaluate the 4D dose calculation process implemented in a commercial treatment planning system. The method could potentially be developed as a fully-automatic QA method in image guided adaptive radiation therapy (IGART).

SU-E-T-526: Evaluation of Dose Mapping Errors via Use of a Volume-Based Dose Mapping Method.

PURPOSE: To quantify dose mapping errors (DMEs) of a point-based dose mapping method for 4D lung treatment plans. METHODS: Point-based dose mapping methods utilize deformation vector fields (DVFS) to interpolate dose from a deformed image. Volume-based dose mapping methods consider the volume overlap between deformed and reference voxels; defining dose as the integral energy divided by the integral mass of the voxel, and conserving integral dose . DME is defined as the dose differences between volume-based and point-based mapped dose (DME=(DpointBased-DvolumeBased)/DRx). The DME for a 4D lung case is compared with a bitmap DME method, both using a Pinnacle research version 8.1y DVF. DME is computed for ten 4D lung cases (five 10 phases, five 3 phase) with Pinnacle research version 9.100 DVFs. Multi-phase accumulated 4D DMEs are also evaluated. RESULTS: For all cases, the largest DMEs are located in the dose/density gradient regions. With Pinnacle 8.1y DVF, mapping dose from phase 9 to phase 0, results in a DME=-0.2%±6.1% (range of -76%∼112%). The same case with Pinnacle 9.100 DVFs, DME=0.3%±4.8%(-41%∼32%). Locations of large DME are consistent with those from the bitmap method. For the ten 4D lung cases, accumulated mean DME are within ±0.07% (std. deviations: 1∼5%, range -102%∼64%). Maximum tumor DMEs are less than 30cGy (DRx=7200cGy) for all patients. CONCLUSIONS: Due to its inherent integral dose conservation, volume-based dose mapping methods can quantify errors in point-based dose mapping methods. While mean DME values are small for the cases tested, standard deviations near 5% indicate that a substantial number of voxels have ∼5% dose mapping errors, however these dose errors do not occur in the target structures. Work supported by NIH P01CA116602.

SU-E-J-103: Characteristics of Bladder Wall Deformation as a Function of Bladder Filling.

PURPOSE: ICRU report 83 recommends delineation of the wall for hollow organs such as the bladder. For image guided radiotherapy, there is no guidance as to how to delineate deformed walls as the filling of hollow organs change. This work investigates characteristics of bladder wall deformation as a function of bladder filling in a controlled process. METHODS: CT images of a fresh pig bladder are obtained in-air with different bladder air fillings. A plastic hose inserted into and glued to the bladder neck forms an air-tight seal for filling with a syringe. At each air-filling level, a helical CT (90kV, 90mAs) of the bladder is obtained. The pixel size on all CT images is <0.5 mm. Images are imported into a commercial planning system for delineation and statistical evaluation. Bladder walls at each filling status are auto-contoured, then edited for quality assurance slice by slice. The auto-contouring threshold is selected to obtain consistent volumes of the resulting region-of-interest at each filling status. RESULTS: When the bladder wall interior volume increases by 360 cm3 from injecting air, the wall thickness decreases from 2.9 mm to 1.2 mm. The decrease in wall thickness is accompanied by a decrease in the wall CT number. CONCLUSIONS: For a pig bladder, the wall thickness decreases with increased air filling. The CT number (hence apparent density) of the volume decreases as the bladder expands. Further investigation is ongoing to determine if the apparent density decrease is real, due to CT reconstruction, or due to the bladder being in an air, rather than liquid environment. Characterization of hollow organ wall thickness variations may be important for image guided radiation therapy and organ wall dose evaluation. Support: P01CA116602.

SU-F-BRCD-06: Multiple Anatomy Optimization of Accumulated Dose.

PURPOSE: Multiple anatomy optimization (MAO) utilizing deformable dose accumulation on entire 4DCT data sets is implemented to overcome ambiguity between optimal dose defined on a single anatomy and optimal accumulated dose resulting from dose delivery to moving and deforming anatomy. METHODS: Six lung cancer patients are planned using two methods of radiotherapy optimization: the internal target volume (ITV) envelope method and MAO, which simultaneously optimizes a single fluence for delivery to all 10 breathing phases such that the accumulated dose satisfies the plan objectives. Target dose is constrained to 70 Gy. The ITV-plan is optimized on a single breathing phase with the planning target volume defined as the ITV; the MAO target is the moving CTV. MAO is compared to single image ITV optimization based on the accumulated dose assuming equal monitor-units to each phase. Dose-volume differences between single image estimations and 10-image accumulation are examined. RESULTS: Single image optimal dose distributions overestimate target V70 by 4.2%±3.1% (average, one standard deviation) and in five of six cases ipsilateral lung V20 is underestimated (1.4%±0.9%). For these five cases, MAO increases V70 by 2.8%±2.5% (maximum of 6% increase in V70) and reduces ipsilateral lung V20 by up to 3% (average decrease of 1.2%±1.3%). Contralateral lung V20, esophagus V25, and heart V30 are also reduced by up to 5%, 3%, and 3%. For the sixth case, lung tumor motion is on the order of the dose voxel size (3mm), and MAO did not improve upon the ITV plan. CONCLUSIONS: Dose-volume optimization on a stationary image does not ensure accumulated dose coverage to the moving CTV. Multiple anatomy optimization can remove dose ambiguity and improve plan quality. P01CA11602 and Philips Medical Systems.

SU-E-T-553: Dose-Mass Vs. Dose-Volume Optimization: A Phantom Study.

PURPOSE: To demonstrate the merits of mass-based optimization in comparison with volume-based optimization using a simple test phantom. METHODS: Dose-volume-histogram-based (DVH-based) quadratic objective functions are converted into dose-mass-histogram-based (DMH-based) objective functions by multiplying per-voxel volumes by per-voxel densities within the objective. A digital phantom with a 1.0 g/cm3 target is constructed for irradiation with two beams: one beam path contains a 0.2 g/cm3 volume-of-interest (VOI0.2) while the orthogonal beam-path contains an equal-volume 0.8 g/cm3 VOI (VOI0.8). Monitor-units are computed to achieve a 100 cGy average target dose for each individual beam, and for two-beam DVH-based and DMH-based optimizations. RESULTS: For single-beam irradiation through VOI0.2, the average dose to VOI0.2 is 20.5 cGy. For single-beam irradiation through VOI0.8, the average dose to VOI0.8 is 25.2 cGy. Traversing the low density volume results in ∼23% lower dose. When DVH- and DMH-based optimizations are performed such that target dose-volume-histograms of the optimizations match, for the DVH optimization 60% vs. 40% of the dose is delivered through VOI0.2 vs. VOI0.8. For DMH-optimization, the split between dose delivered through VOI0.2 vs. VOI0.8 is 70% vs. 30%. CONCLUSIONS: When density is constant, there is no difference between DVH- and DMH-based optimizations. However, in heterogeneous media, DMH and DVH solutions differ when low and high density materials have the same dose objectives. Delivering target dose through lower density VOIs facilitates target dose deposition due to a decrease in attenuating material, and the decreased attenuation lowers dose to the low density VOI. From mathematical and physical points of view dose-mass optimization is more general than dose-volume optimization.

The effect of uterine motion and uterine margins on target and normal tissue doses in intensity modulated radiation therapy of cervical cancer.

In intensity modulated radiation therapy (IMRT) of cervical cancer, uterine motion can be larger than cervix motion, requiring a larger clinical target volume to planning target volume (CTV-to-PTV) margin around the uterine fundus. This work simulates different motion models and margins to estimate the dosimetric consequences. A virtual study used image sets from ten patients. Plans were created with uniform margins of 1 cm (PTV(A)) and 2.4 cm (PTV(C)), and a margin tapering from 2.4 cm at the fundus to 1 cm at the cervix (PTV(B)). Three inter-fraction motion models (MM) were simulated. In MM1, all structures moved with normally distributed rigid body translations. In MM2, CTV motion was progressively magnified as one moved superiorly from the cervix to the fundus. In MM3, both CTV and normal tissue motion were magnified as in MM2, modeling the scenario where normal tissues move into the void left by the mobile uterus. Plans were evaluated using static and percentile DVHs. For a conventional margin (PTV(A)), quasi-realistic uterine motion (MM3) reduces fundus dose by about 5 Gy and increases normal tissue volumes receiving 30-50 Gy by ∼5%. A tapered CTV-to-PTV margin can restore fundus and CTV doses, but will increase normal tissue volumes receiving 30-50 Gy by a further ∼5%.

A pseudoinverse deformation vector field generator and its applications.

PURPOSE: To present, implement, and test a self-consistent pseudoinverse displacement vector field (PIDVF) generator, which preserves the location of information mapped back-and-forth between image sets. METHODS: The algorithm is an iterative scheme based on nearest neighbor interpolation and a subsequent iterative search. Performance of the algorithm is benchmarked using a lung 4DCT data set with six CT images from different breathing phases and eight CT images for a single prostrate patient acquired on different days. A diffeomorphic deformable image registration is used to validate our PIDVFs. Additionally, the PIDVF is used to measure the self-consistency of two nondiffeomorphic algorithms which do not use a self-consistency constraint: The ITK Demons algorithm for the lung patient images and an in-house B-Spline algorithm for the prostate patient images. Both Demons and B-Spline have been QAed through contour comparison. Self-consistency is determined by using a DIR to generate a displacement vector field (DVF) between reference image R and study image S (DVF(R-S)). The same DIR is used to generate DVF(S-R). Additionally, our PIDVF generator is used to create PIDVF(S-R). Back-and-forth mapping of a set of points (used as surrogates of contours) using DVF(R-S) and DVF(S-R) is compared to back-and-forth mapping performed with DVF(R-S) and PIDVF(S-R). The Euclidean distances between the original unmapped points and the mapped points are used as a self-consistency measure. RESULTS: Test results demonstrate that the consistency error observed in back-and-forth mappings can be reduced two to nine times in point mapping and 1.5 to three times in dose mapping when the PIDVF is used in place of the B-Spline algorithm. These self-consistency improvements are not affected by the exchanging of R and S. It is also demonstrated that differences between DVF(S-R) and PIDVF(S-R) can be used as a criteria to check the quality of the DVF. CONCLUSIONS: Use of DVF and its PIDVF will improve the self-consistency of points, contour, and dose mappings in image guided adaptive therapy.

Coverage optimized planning: probabilistic treatment planning based on dose coverage histogram criteria.

This work (i) proposes a probabilistic treatment planning framework, termed coverage optimized planning (COP), based on dose coverage histogram (DCH) criteria; (ii) describes a concrete proof-of-concept implementation of COP within the PINNACLE treatment planning system; and (iii) for a set of 28 prostate anatomies, compares COP plans generated with this implementation to traditional PTV-based plans generated with planning criteria approximating those in the high dose arm of the Radiation Therapy Oncology Group 0126 protocol. Let Dv denote the dose delivered to fractional volume v of a structure. In conventional intensity modulated radiation therapy planning, Dv has a unique value derived from the static (planned) dose distribution. In the presence of geometric uncertainties (e.g., setup errors) Dv assumes a range of values. The DCH is the complementary cumulative distribution function of D(v+). DCHs are similar to dose volume histograms (DVHs). Whereas a DVH plots volume v versus dose D, a DCH plots coverage probability Q versus D. For a given patient, Q is the probability (i.e., percentage of geometric uncertainties) for which the realized value of Dv exceeds D. PTV-based treatment plans can be converted to COP plans by replacing DVH optimization criteria with corresponding DCH criteria. In this approach, PTVs and planning organ at risk volumes are discarded, and DCH criteria are instead applied directly to clinical target volumes (CTVs) or organs at risk (OARs). Plans are optimized using a similar strategy as for DVH criteria. The specific implementation is described. COP was found to produce better plans than standard PTV-based plans, in the following sense. While target OAR dose tradeoff curves were equivalent to those for PTV-based plans, COP plans were able to exploit slack in OAR doses, i.e., cases where OAR doses were below their optimization limits, to increase target coverage. Specifically, because COP plans were not constrained by a predefined PTV, they were able to provide wider dosimetric margins around the CTV, by pushing OAR doses up to, but not beyond, their optimization limits. COP plans demonstrated improved target coverage when averaged over all 28 prostate anatomies, indicating that the COP approach can provide benefits for many patients. However, the degree to which slack OAR doses can be exploited to increase target coverage will vary according to the individual patient anatomy. The proof-of-concept COP implementation investigated here utilized a probabilistic DCH criteria only for the CTV minimum dose criterion. All other optimization criteria were conventional DVH criteria. In a mature COP implementation, all optimization criteria will be DCH criteria, enabling direct planning control over probabilistic dose distributions. Further research is necessary to determine the benefits of COP planning, in terms of tumor control probability and/or normal tissue complication probabilities.

A comparison of HDR brachytherapy and IMRT techniques for dose escalation in prostate cancer: a radiobiological modeling study.

A course of one to three large fractions of high dose rate (HDR) interstitial brachytherapy is an attractive alternative to intensity modulated radiation therapy (IMRT) for delivering boost doses to the prostate in combination with additional external beam irradiation for intermediate risk disease. The purpose of this work is to quantitatively compare single-fraction HDR boosts to biologically equivalent fractionated IMRT boosts, assuming idealized image guided delivery (igIMRT) and conventional delivery (cIMRT). For nine prostate patients, both seven-field IMRT and HDR boosts were planned. The linear-quadratic model was used to compute biologically equivalent dose prescriptions. The cIMRT plan was evaluated as a static plan and with simulated random and setup errors. The authors conclude that HDR delivery produces a therapeutic ratio which is significantly better than the conventional IMRT and comparable to or better than the igIMRT delivery. For the HDR, the rectal gBEUD analysis is strongly influenced by high dose DVH tails. A saturation BED, beyond which no further injury can occur, must be assumed. Modeling of organ motion uncertainties yields mean outcomes similar to static plan outcomes.

A method to improve accuracy and precision of water surface identification for photon depth dose measurements.

The objective of this study is to present a method to reduce the setup error inherent in clinical depth dose measurements and, in doing so, to improve entrance dosimetry measurement reliability. Ionization chamber (IC) depth dose measurements are acquired with the depth scan extended into the air above the water surface. An inflection region is obtained in each resulting percent depth ionization (PDI) curve that can be matched against other measurements or to an inflection region obtained from an analogous Monte Carlo (MC) simulation. Measurements are made with various field sizes for the 6 and 18 MV photon beams, with and without a Pb foil in the beam, to determine the sensitivity of the dose inflection region to the beam conditions. The offset between reference and test data set inflection regions is quantified using two separate methods. When comparing sets of measured data, maxima in the second derivative of ionization are compared. When comparing measured data to MC simulation, the offset that minimizes the sum of squared differences between the reference and test curves in the ionization inflection region is found. These methods can be used to quantify the offset between an initial setup (test) position and the true surface (reference) position. The ionization inflection location is found to be insensitive to changes in field size, electron contamination, and beam energy. Data from a single reference condition should be sufficient to identify the surface location. The method of determining IC offsets is general and should be applicable to any IC and other radiation sources. The measurement method could reduce the time and effort required in the initial IC setup at a water surface as setup errors can be corrected offline. Given a reliable set of reference data to compare with, this method could increase the ability of quality assurance (QA) measurements to detect discrepancies in beam output as opposed to discrepancies in IC localization. Application of the measurement method standardizes the procedure for localizing cylindrical ICs at a water surface and thereby improves the reliability of measurements taken with these devices at all depths.

Coverage-based treatment planning: optimizing the IMRT PTV to meet a CTV coverage criterion.

This work demonstrates an iterative approach-referred to as coverage-based treatment planning-designed to produce treatment plans that ensure target coverage for a specified percentage of setup errors. In this approach the clinical target volume to planning target volume (CTV-to-PTV) margin is iteratively adjusted until the specified CTV coverage is achieved. The advantage of this approach is that it automatically compensates for the dosimetric margin around the CTV, i.e., the extra margin that is created when the dose distribution extends beyond the PTV. When applied to 27 prostate plans, this approach reduced the average CTV-to-PTV margin from 5 to 2.8 mm. This reduction in PTV size produced a corresponding decrease in the volume of normal tissue receiving high dose. The total volume of tissue receiving > or =65 Gy was reduced on average by 19.3% or about 48 cc. Individual reductions varied from 8.7% to 28.6%. The volume of bladder receiving > or =60 Gy was reduced on average by 5.6% (reductions for individuals varied from 1.7% to 10.6%), and the volume of periprostatic rectum receiving > or =65 Gy was reduced on average by 4.9% (reductions for individuals varied from 0.9% to 12.3%). The iterative method proposed here represents a step toward a probabilistic treatment planning algorithm which can generate dose distributions (i.e., treated volumes) that closely approximate a specified level of coverage in the presence of geometric uncertainties. The general principles of coverage-based treatment planning are applicable to arbitrary treatment sites and delivery techniques. Importantly, observed deviations between coverage implied by specified CTV-to-PTV margins and coverage achieved by a given treatment plan imply a generic need to perform coverage probability analysis on a per-plan basis to ensure that the desired level of coverage is achieved.

Evaluation of dose prediction errors and optimization convergence errors of deliverable-based head-and-neck IMRT plans computed with a superposition/convolution dose algorithm.

The purpose of this study is to evaluate dose prediction errors (DPEs) and optimization convergence errors (OCEs) resulting from use of a superposition/convolution dose calculation algorithm in deliverable intensity-modulated radiation therapy (IMRT) optimization for head-and-neck (HN) patients. Thirteen HN IMRT patient plans were retrospectively reoptimized. The IMRT optimization was performed in three sequential steps: (1) fast optimization in which an initial nondeliverable IMRT solution was achieved and then converted to multileaf collimator (MLC) leaf sequences; (2) mixed deliverable optimization that used a Monte Carlo (MC) algorithm to account for the incident photon fluence modulation by the MLC, whereas a superposition/convolution (SC) dose calculation algorithm was utilized for the patient dose calculations; and (3) MC deliverable-based optimization in which both fluence and patient dose calculations were performed with a MC algorithm. DPEs of the mixed method were quantified by evaluating the differences between the mixed optimization SC dose result and a MC dose recalculation of the mixed optimization solution. OCEs of the mixed method were quantified by evaluating the differences between the MC recalculation of the mixed optimization solution and the final MC optimization solution. The results were analyzed through dose volume indices derived from the cumulative dose-volume histograms for selected anatomic structures. Statistical equivalence tests were used to determine the significance of the DPEs and the OCEs. Furthermore, a correlation analysis between DPEs and OCEs was performed. The evaluated DPEs were within +/- 2.8% while the OCEs were within 5.5%, indicating that OCEs can be clinically significant even when DPEs are clinically insignificant. The full MC-dose-based optimization reduced normal tissue dose by as much as 8.5% compared with the mixed-method optimization results. The DPEs and the OCEs in the targets had correlation coefficients greater than 0.71, and there was no correlation for the organs at risk. Because full MC-based optimization results in lower normal tissue doses, this method proves advantageous for HN IMRT optimization.

Evaluation of dosimetric margins in prostate IMRT treatment plans.

This work introduces a new concept--the dosimetric margin distribution (DMD)--and uses it to explain the sensitivity of a group of prostate IMRT treatment plans to patient setup errors. Prior work simulated the effect of setup errors on 27 prostate IMRT treatment plans and found the plans could tolerate larger setup errors than predicted by the van Herk margin formula. The conjectured reason for this disagreement was a breakdown in van Herk's assumption that the planned dose distribution conforms perfectly to target structures. To resolve the disagreement, this work employed the same 27 plans to evaluate the actual margin distributions that exist between: (i) the clinical target volume (CTV) and planning target volume (PTV) and (ii) the CTV and PTV minimum dose isodose surface. These distributions were evaluated for both prostate and nodal targets. Distribution (ii) is the DMD. The dosimetric margin in a given direction determines the probability that the CTV will be underdosed due to setup errors in that direction. Averaging over 4 pi sr gives the overall probability of CTV coverage. Minimum doses for prostate and nodal PTVs were obtained from dose volume histograms. Corresponding isodose surfaces were created and converted to regions of interest (ROIs). CTV, PTV, and isodose ROIs were saved as mesh files and then imported into a computational geometry application which calculated distances between meshes (i.e., margins) in 614 discrete directions covering 4 pi sr in 10 deg increments. Measured prostate CTV-to-PTV margins were close to the nominal value of 0.5 cm specified in the treatment planning protocol. However, depending on direction, prostate dosimetric margins ranged from 0.5 to 3 cm, reflecting the imperfect conformance of the planned dose distribution to the prostate PTV. For the nodal CTV, the nominal CTV-to-PTV margin employed in treatment planning was again 0.5 cm. However, due to the planning protocol, the nodal PTV follows the surface of the nodal CTV in several places, ensuring that there is no room for rigid body motion of the nodal CTV inside the nodal PTV. Measured nodal CTV-to-PTV margins were therefore zero, while nodal dosimetric margins ranged from 0.2 to 2.8 cm. Prostate and nodal target coverage were found to be well correlated with the measured DMDs, thereby resolving the apparent disagreement with our prior results. The principal conclusion is that target coverage in the presence of setup errors should be evaluated using the DMD, rather than the CTV-to-PTV margin distribution. The DMD is a useful planning metric, which generalizes the ICRU conformity index. DMDs could vary with number of beams, beam arrangements, TPS, and treatment site.

A strategy to correct for intrafraction target translation in conformal prostate radiotherapy: simulation results.

A strategy is proposed in which intrafraction internal target translation is corrected for by repositioning the multileaf collimator position aperture to conform to the new target pose in the beam projection, and the beam monitor units are adjusted to account for the change in the geometric relationship between the target and the beam. The purpose of this study was to investigate the dosimetric stability of the prostate and critical structures in the presence of internal target translation using the dynamic compensation strategy. Twenty-five previously treated prostate cancer patients were replanned using a four-field conformal technique to deliver 72 Gy to 95% of the planning target volume (PTV). Internal translation was introduced by displacing the prostate PTV (no rotation or deformation was considered). Thirty-six randomly selected isotropic displacements of magnitude 0.5, 1.0, 1.5 and 2.0 cm were sampled for each patient, for a total of 3600 errors. Due to their anatomic relation to the prostate, the rectum and bladder contours were also moved with the same magnitude and direction as the prostate. The dynamic compensation strategy was used to correct each of these errors by conforming the beam apertures to the new target pose and adjusting the monitor units using inverse-square and off-axis factor corrections. The dynamic compensation strategy plans were then compared to the original treatment plans via dose-volume histogram (DVH) analysis. Changes of more than 5% of the prescription dose (3.6 Gy) were deemed clinically significant. Compared to the original treatment plans, the dynamic compensation strategy produced small discrepancies in isodose distributions and DVH analyses for all structures considered apart from the femoral heads. These differences increased with the magnitude of the internal motion. Coverage of the PTV was excellent: D5, D95, and Dmean were not increased or decreased by more than 5% of the prescription dose for any of the 3600 simulated internal motion shifts. Dose increases for adjacent organs at risk were rare. D33 of the rectum and D20 of the bladder were increased by more than 5% of the prescription dose in 9 and 1 instances of the 3600 sampled internal motion shifts, respectively. Dmean of the right femoral head increased by more than 5% of the prescription dose in 651 (18%) internal motion shifts, predominantly due to the projection of the lateral beams through the femoral head for anterior prostate motion. However, D2 was not increased by more than 5% for any of the internal motion shifts. These data demonstrate the robustness of the proposed dynamic compensation strategy for correction of internal motion in conformal prostate radiotherapy, with minimal deviation from the original treatment plans even for errors exceeding those commonly encountered in the clinic. The compensation strategy could be performed automatically with appropriate enhancements to available delivery software.

Dose calculation validation of Vmc++ for photon beams.

The radiation therapy specific Voxel Monte Carlo (VMC+ +) dose calculation algorithm achieves a dramatic improvement in MC dose calculation efficiency for radiation therapy treatment planning dose evaluation compared with other MC algorithms. This work aims to validate VMC+ + for radiation therapy photon beam planning. VMC++ was validated with respect to the well-benchmarked EGS-based DOSXYZnrc by comparing depth dose and lateral profiles for field sizes ranging from 1 X 1 to 40 x 40 cm(2) for 6 and 18 MV beams in a homogeneous water phantom and in a simulated bone-lung-bone phantom. Patient treatment plan dose distributions were compared for five prostate plans and five head-and-neck (H/N) plans, all using intensity-modulated radiotherapy beams. For all tests, the same incident particles were used in both codes to isolate differences due to modeling of the radiation source. Voxel-by-voxel observed differences were analyzed to distinguish between systematic and purely statistical differences. Dose-volume-histogram-derived dose indices were compared for the patient plans. For the homogeneous water phantom and the bone-lung-bone phantom, the depth dose curve predicted by VMC+ + agreed with that predicted by DOSXYZnrc within expected statistical uncertainty in all voxels except the surface voxel of the water phantom, where VMC+ + predicted a lower dose. When the electron cutoff parameter was decreased for both codes, the surface voxel agreed within expected statistical uncertainty. For prostate plans, the most severe difference between the codes resulted in 55% of the voxels showing a systematic difference of 0.32% of maximum dose. For H/N plans, the largest difference observed resulted in 2% of the voxels showing a systematic difference of 0.98% of maximum dose. For the prostate plans, the most severe difference in the planning target volume D95 was 0.4%, the rectum D35 was 0.2%, the rectum DI7 was 0.2%, the bladder D50 was 0.3% and the bladder D25 was 0.3%. For the H/N plans, the most severe difference in the gross tumor volume D98 was 0.4%, the clinical target volume D90 was 0.2%, the nodes D90 was 0.2%, the parotids D95 was 0.8%, and the cord D2 was 0.8%. All of these differences are clinically insignificant. VMC++ showed an average efficiency gain over DOSXYZnrc of at least an order of magnitude without introducing significant systematic bias. VMC + + can be used for photon beam MC patient dose computations without a clinically significant loss in accuracy.